Total Payments
$383,274
2024 Payments
$44,821
Companies
25
Transactions
223
Medicare Patients
312
Medicare Billing
$82,233
Payment Breakdown by Category
Consulting$264,153 (68.9%)
Research$57,956 (15.1%)
Other$25,150 (6.6%)
Travel$23,328 (6.1%)
Education$9,190 (2.4%)
Food & Beverage$3,497 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $264,153 | 55 | 68.9% |
| Unspecified | $57,956 | 34 | 15.1% |
| Travel and Lodging | $23,328 | 31 | 6.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,930 | 22 | 6.0% |
| Education | $9,190 | 2 | 2.4% |
| Food and Beverage | $3,497 | 78 | 0.9% |
| Honoraria | $2,220 | 1 | 0.6% |
Payments by Type
General
$325,318
189 transactions
Research
$57,956
34 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $111,389 | 64 | $0 (2024) |
| PFIZER INC. | $47,350 | 39 | $0 (2023) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $33,964 | 15 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $30,816 | 7 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $29,164 | 11 | $0 (2021) |
| Eli Lilly and Company | $22,236 | 29 | $0 (2022) |
| GlaxoSmithKline, LLC. | $20,000 | 2 | $0 (2023) |
| Daiichi Sankyo Inc. | $16,818 | 7 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $14,136 | 4 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $11,070 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44,821 | 18 | AstraZeneca Pharmaceuticals LP ($23,281) |
| 2023 | $22,479 | 9 | GlaxoSmithKline, LLC. ($8,800) |
| 2022 | $18,215 | 9 | E.R. Squibb & Sons, L.L.C. ($8,610) |
| 2021 | $56,329 | 25 | Novartis Pharmaceuticals Corporation ($18,122) |
| 2020 | $107,146 | 54 | Celgene Corporation ($44,090) |
| 2019 | $49,608 | 28 | Celgene Corporation ($25,937) |
| 2018 | $43,299 | 39 | Celgene Corporation ($25,704) |
| 2017 | $41,376 | 41 | Sandoz Inc. ($10,631) |
All Payment Transactions
223 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Genmab U.S., Inc. | — | Food and Beverage | In-kind items and services | $78.09 | General |
| 12/09/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $45.18 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 12/06/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| 12/05/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $4.23 | General |
| Category: Genetically Defined Disease | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $21,920.00 | General |
| 07/10/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Travel and Lodging | In-kind items and services | $926.11 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Travel and Lodging | In-kind items and services | $162.63 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | Cash or cash equivalent | $67.61 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Travel and Lodging | In-kind items and services | $13,066.00 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Consulting Fee | Cash or cash equivalent | $2,445.00 | General |
| Category: Oncology | ||||||
| 03/06/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $620.32 | General |
| 03/04/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $374.18 | General |
| 03/04/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $221.64 | General |
| 03/04/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $83.54 | General |
| 03/04/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $61.38 | General |
| 02/20/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,460.00 | General |
| 01/03/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $2,220.00 | General |
| Category: Genetically Defined Disease | ||||||
| 12/07/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $106.78 | General |
| Category: Genetically Defined Disease | ||||||
| 12/07/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $41.55 | General |
| Category: Genetically Defined Disease | ||||||
| 07/28/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 07/07/2023 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $150.39 | General |
| 05/10/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $7,535.00 | General |
| Category: Oncology | ||||||
| 03/15/2023 | PFIZER INC. | DAURISMO (Drug), MYLOTARG | — | In-kind items and services | $3,200.00 | Research |
| Study: GLASDEGIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/09/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AML CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $19,330 | 15 |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) (ACE-536-MDS-001) | Celgene Corporation | $7,233 | 2 |
| Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (AZA-MDS-006) | Celgene Corporation | $4,962 | 1 |
| AG-221-AML-004 | Celgene Corporation | $4,018 | 1 |
| GLASDEGIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| DSP-7888 | Sumitomo Dainippon Pharma Co., Ltd. | $2,700 | 1 |
| AG-221-C-001 | Celgene Corporation | $2,509 | 1 |
| A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (AG-221-AML-004) | Celgene Corporation | $2,000 | 1 |
| AG-221-AML-004 - A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia H | Celgene Corporation | $2,000 | 1 |
| Connect MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | Celgene Corporation | $1,800 | 1 |
| A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation (AG-221-C-001) | Celgene Corporation | $1,620 | 1 |
| AZA-MDS-006 - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | Celgene Corporation | $1,524 | 1 |
| ACE-536-MDS-001 - A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) | Celgene Corporation | $1,409 | 1 |
| ACE-011-MDS-001 | Celgene Corporation | $1,156 | 1 |
| AG-221-C-001 - A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hemat | Celgene Corporation | $1,156 | 1 |
| ACE-011-MF-PI-0005 | Celgene Corporation | $578.00 | 1 |
| CC-5013-MDS-003 - A Multicenter, Single-Arm, Open-Label Study of The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion-Dependent Subjects with Myelodysplastic Syndromes Associated with a Del | Celgene Corporation | $578.00 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $143.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 97 | 300 | $114,001 | $30,108 |
| 2022 | 3 | 80 | 199 | $73,250 | $19,317 |
| 2021 | 3 | 58 | 113 | $45,181 | $12,346 |
| 2020 | 3 | 77 | 307 | $132,364 | $20,461 |
Total Patients
312
Total Services
919
Medicare Billing
$82,233
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 38 | 131 | $39,169 | $10,423 | 26.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 84 | $33,516 | $8,693 | 25.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 25 | 64 | $27,456 | $7,918 | 28.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 21 | 21 | $13,860 | $3,074 | 22.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 37 | 127 | $37,973 | $9,742 | 25.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 24 | 53 | $22,737 | $6,670 | 29.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 19 | 19 | $12,540 | $2,906 | 23.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 18 | 69 | $20,761 | $6,023 | 29.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 24 | 24 | $15,840 | $3,749 | 23.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 16 | 20 | $8,580 | $2,574 | 30.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 39 | 169 | $60,661 | $10,144 | 16.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 26 | 125 | $65,125 | $9,234 | 14.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 13 | $6,578 | $1,083 | 16.5% |
About Dr. Mikkael Sekeres, MD
Dr. Mikkael Sekeres, MD is a Hematology & Oncology healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497710941.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mikkael Sekeres, MD has received a total of $383,274 in payments from pharmaceutical and medical device companies, with $44,821 received in 2024. These payments were reported across 223 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($264,153).
As a Medicare-enrolled provider, Sekeres has provided services to 312 Medicare beneficiaries, totaling 919 services with total Medicare billing of $82,233. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Miami, FL
- Active Since 04/19/2006
- Last Updated 02/06/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1497710941
Products in Payments
- DAURISMO (Drug) $41,970
- Luspatercept (Drug) $16,713
- Vanflyta (Drug) $14,268
- KEYTRUDA (Biological) $14,136
- Revlimid (Drug) $13,968
- Idhifa (Drug) $13,303
- KYMRIAH (Biological) $9,174
- JEMPERLI (Biological) $8,800
- LYNPARZA (Drug) $7,535
- CC-486 (Drug) $6,486
- FARYDAK (Drug) $5,600
- TIBSOVO (Drug) $3,300
- Reblozyl (Drug) $3,223
- DSP-7888 (Drug) $2,700
- XPOVIO (Drug) $2,626
- Venclexta (Drug) $2,580
- PYRUKYND (Drug) $2,373
- ONUREG (Drug) $2,250
- Vidaza (Drug) $1,800
- Sotatercept (Drug) $1,734
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Miami
Dr. Steven Fein, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Carl Landgren, Md, MD
Hematology & Oncology — Payments: $751,068
Hematology & Oncology $751,068
Dr. Fernando De Zarraga, M.d, M.D
Hematology & Oncology — Payments: $649,574
Hematology & Oncology $649,574
Mr. Neil Nagovski, Md, MD
Hematology & Oncology — Payments: $533,284
Hematology & Oncology $533,284
Srikanth Nagalla, Md, MD
Hematology & Oncology — Payments: $510,589
Hematology & Oncology $510,589
Raja Mudad, Md, MD
Hematology & Oncology — Payments: $442,163
Hematology & Oncology $442,163